![The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity - The Lancet Respiratory Medicine The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/cc701e18-f412-4e02-bde7-57fe8cff6720/gr1.jpg)
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity - The Lancet Respiratory Medicine
![Frontiers | COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes Frontiers | COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes](https://www.frontiersin.org/files/Articles/599736/fimmu-11-599736-HTML/image_m/fimmu-11-599736-g001.jpg)
Frontiers | COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes
![JCM | Free Full-Text | Direct Comparison of Clinical Characteristics, Outcomes, and Risk Prediction in Patients with COVID-19 and Controls—A Prospective Cohort Study JCM | Free Full-Text | Direct Comparison of Clinical Characteristics, Outcomes, and Risk Prediction in Patients with COVID-19 and Controls—A Prospective Cohort Study](https://pub.mdpi-res.com/jcm/jcm-10-02672/article_deploy/html/images/jcm-10-02672-ag-550.jpg?1684148488)
JCM | Free Full-Text | Direct Comparison of Clinical Characteristics, Outcomes, and Risk Prediction in Patients with COVID-19 and Controls—A Prospective Cohort Study
Paper-Based Biosensors for COVID-19: A Review of Innovative Tools for Controlling the Pandemic | ACS Omega
![Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis - The Lancet Microbe Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis - The Lancet Microbe](https://www.thelancet.com/cms/attachment/6b359dc0-0eb9-4e03-9941-e00e5bc17913/gr1.jpg)
Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis - The Lancet Microbe
![Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants - ScienceDirect Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2589004223002018-fx1.jpg)